AGT and cardiac hypertrophy: In recent years, it has been shown that SIRT2 can deacetylate hepatic kinase B1 and promote the activation of the AMP-activated protein kinase pathway, thereby inhibiting aging-related and/or angiotensin II-induced pathological cardiac hypertrophy [117].